These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 20571610)

  • 1. Oxybutynin topical and transdermal formulations: an update.
    Staskin DR; Salvatore S
    Drugs Today (Barc); 2010 Jun; 46(6):417-25. PubMed ID: 20571610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of oxybutynin chloride topical gel: effects of application site, baths, sunscreen and person-to-person transference.
    Dmochowski RR; Newman DK; Sand PK; Rudy DC; Caramelli KE; Thomas H; Hoel G
    Clin Drug Investig; 2011; 31(8):559-571. PubMed ID: 21721591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder.
    Staskin DR; Robinson D
    Expert Opin Pharmacother; 2009 Dec; 10(18):3103-11. PubMed ID: 19954278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transdermal drug delivery treatment for overactive bladder.
    Dmochowski RR; Starkman JS; Davila GW
    Int Braz J Urol; 2006; 32(5):513-20. PubMed ID: 17081319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transdermal oxybutynin: a new treatment for overactive bladder.
    Davila GW
    Expert Opin Pharmacother; 2003 Dec; 4(12):2315-24. PubMed ID: 14640930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxybutynin gel for the treatment of overactive bladder.
    Gomelsky A; Dmochowski RR
    Expert Opin Pharmacother; 2012 Jun; 13(9):1337-43. PubMed ID: 22607010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of transdermal oxybutynin in the treatment of overactive bladder.
    Sahai A; Mallina R; Dowson C; Larner T; Khan MS
    Int J Clin Pract; 2008 Jan; 62(1):167-70. PubMed ID: 18173821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of oxybutynin chloride topical gel for women with overactive bladder syndrome.
    Sand PK; Davila GW; Lucente VR; Thomas H; Caramelli KE; Hoel G
    Am J Obstet Gynecol; 2012 Feb; 206(2):168.e1-6. PubMed ID: 21963104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxybutynin topical gel in the treatment of overactive bladder.
    Davila GW
    Open Access J Urol; 2010 Jun; 2():91-8. PubMed ID: 24198618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evolution of transdermal therapy for overactive bladder.
    Sand PK
    Curr Urol Rep; 2009 Sep; 10(5):338-41. PubMed ID: 19709479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity.
    Cartwright PC; Coplen DE; Kogan BA; Volinn W; Finan E; Hoel G
    J Urol; 2009 Oct; 182(4):1548-54. PubMed ID: 19683731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transdermal oxybutynin for overactive bladder.
    Davila GW; Starkman JS; Dmochowski RR
    Urol Clin North Am; 2006 Nov; 33(4):455-63, viii. PubMed ID: 17011381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder.
    Goldenberg MM
    Clin Ther; 1999 Apr; 21(4):634-42. PubMed ID: 10363730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of oxybutynin chloride topical gel for overactive bladder.
    Lucente VR; Staskin DR; De E
    Open Access J Urol; 2011 Apr; 3():35-42. PubMed ID: 24198634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study.
    Staskin DR; Dmochowski RR; Sand PK; Macdiarmid SA; Caramelli KE; Thomas H; Hoel G
    J Urol; 2009 Apr; 181(4):1764-72. PubMed ID: 19233423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Propiverine compared to oxybutynin in neurogenic detrusor overactivity--results of a randomized, double-blind, multicenter clinical study.
    Stöhrer M; Mürtz G; Kramer G; Schnabel F; Arnold EP; Wyndaele JJ;
    Eur Urol; 2007 Jan; 51(1):235-42. PubMed ID: 16698176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transdermal oxybutynin.
    Baldwin CM; Keating GM
    Drugs; 2009; 69(3):327-37. PubMed ID: 19275276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New perspectives on the overactive bladder: pharmacokinetics and bioavailability.
    Gupta S; Sathyan G; Mori T
    Urology; 2002 Nov; 60(5 Suppl 1):78-80; discussion 80-1. PubMed ID: 12493362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gelnique (oxybutynin chloride) 10% gel for overactive bladder.
    Lajiness MJ
    Urol Nurs; 2010; 30(4):253-4. PubMed ID: 20949812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxybutynin for treatment of urge urinary incontinence and overactive bladder: an updated review.
    Abramov Y; Sand PK
    Expert Opin Pharmacother; 2004 Nov; 5(11):2351-9. PubMed ID: 15500382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.